R ight ventricular (RV) function is closely coupled with subsequent morbidity and mortality in patients with diseases affecting the right heart chambers. [1] [2] [3] [4] [5] [6] [7] The most common cause of RV dysfunction is chronic left-sided heart failure. Complex factors such as pulmonary hypertension, intrinsic myocardial involvement, ventricular interdependence, and myocardial ischemia lead to RV dysfunction. 1 Therefore, assessment of RV function is clinically important in almost all patients with heart disease. However, the complex geometry of the RV poses a significant limitation to the reliable quantitation of RV volumes and ejection fraction (RVEF) using 2-dimensional transthoracic echocardiography. Although cardiac magnetic resonance (CMR) imaging is the gold standard for the evaluation of RV volumes and RVEF, 8, 9 factors such as cost, portability, time consumption, and contraindications hinder its routine use in every patient. Three-dimensional transthoracic echocardiography (3DTTE) has the advantage of full-volume acquisition of the entire right ventricle, which may overcome the technical and clinical limitations of 2-dimensional transthoracic echocardiography. [10] [11] [12] Recent studies have validated the accuracy of 3DTTE-determined RV volumes and RVEF against CMR 13, 14 and determined the reference values of RV volumes and RVEF in healthy subjects. 15, 16 However, the prognostic value of RVEF is largely unknown. We hypothesized that RVEF assessed by 3DTTE (3DRVEF) would offer incremental value over left ventricular (LV) functional parameters for predicting future cardiac events.
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Methods

Study Subjects
In protocol 1, a total of 60 patients (mean age, 61±15 years; 38 men) who received a clinically indicated CMR examination and also agreed to undergo a 3DTTE examination on the same day were prospectively enrolled.
In protocol 2, we retrospectively selected 842 subjects who underwent both 2-dimensional transthoracic echocardiography and 3DTTE from May 2008 to August 2010 from our 3DTTE database. The exclusion criteria included repeat examinations (n=161), healthy volunteers (n=201) aged <18 years (n=13), and patients with poor image quality (n=21). The final study population consisted of 446 patients. Clinical characteristics, including hypertension, diabetes mellitus, hyperlipidemia, chronic kidney disease (CKD), valvular heart disease, coronary artery disease, and cardiomyopathy, were evaluated at the time of echocardiography examination based on established criteria. CKD was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m 2 . The study protocol was approved by the Ethics Committee in the hospital, and the need for informed consent from study participant was waived.
CMR Acquisition
CMR imaging was performed with a 3T scanner (Discovery 750 W; GE Healthcare, Milwaukee, WI) with a phased-array cardiovascular coil. In each patient, retrospective electrocardiography-gated localizing spin-echo sequences were used to identify the long axis of the heart. Steady-state free precision dynamic gradient-echo cine loops were acquired using retrospective electrocardiographic gating and parallel imaging techniques during 10-to 15-second breath-holds with the following general parameters: 8-mm slice thickness of the imaging planes, 40×40 cm field of view, 200×160 scan matrix, 50° flip angle, 3.8/1.7 ms repetition/echo times, 20 views per segment, and 20 reconstructed cardiac phases. Eight to 16 short-axis slices from the base of the heart to the apex and 3 standard long-axis views were obtained in each patient.
CMR Analysis
CMR RV volumes and RVEF were measured by multiple shortaxis slices using analytic software (Segment, version 2.0; Medviso, AB Lund, Sweden). In each short-axis slice that encompassed the right ventricle, the RV endocardial border was manually traced at the end-diastolic frame and end-systolic frame. For the determination of the RV wall, especially for the selection of the most basal level of the short-axis view, the cine loop was carefully reviewed to determine whether the myocardial cavity became small and the wall became thickened during systole. The disk summation method was used for the calculation of the RV end-diastolic volume and the end-systolic volume (RVESV). RVEF was calculated by the standard formula.
Assessment of LV Diastolic Function
Two-dimensional and Doppler echocardiography was performed using a commercially available ultrasound machine and transducer (iE33; Philips Medical System, Andover, MA, and Vivid7; GE Healthcare, Horten, Norway). From the LV inflow velocities, the E-and A-wave velocities, deceleration time of the E-wave, and E/A velocity ratio were measured. The peak diastolic annular velocity during early diastolic rapid filling (ε′) at both the septal and lateral corners of the mitral annulus was also measured and averaged to calculate the E/ε′ ratio in all subjects. All Doppler measurements were averaged from 3 consecutive beats. The diastolic dysfunction grade was categorized according to the method by Kuwaki et al. 17 Systolic pulmonary arterial pressure was calculated by sum of the transtricuspid pressure gradient using the modified Bernoulli equation and estimated right atrial pressure according to inferior vena cava dimensions and respiratory variations.
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3D Transthoracic Echocardiography
The 3D full-volume data sets were acquired by an iE33 or Epic 7G scanner (Philips Medical Systems) equipped with a fully sampled matrix-array transducer (X3 or X5-1) from the apical approach. To ensure the inclusion of both the left and right ventricles within the pyramidal scan volume with a relatively high volume rate, data sets throughout one cardiac cycle were acquired using the wide-angle mode, wherein 4 wedge-shaped subvolumes were acquired with electrocardiographic gating during a single 5-to 7-second breath-hold. The 3D volumetric assessment of the left atrium was performed by the biplane Simpson's method extracted from 3D data sets with commercially available software (3DQ, QLAB, version 9.0; Philips Medical System). 18 Maximal and minimal left atrial volumes were measured and indexed to the body surface area.
3D Speckle Tracking Echocardiography
The 3D full-volume data sets were analyzed using vendor-independent 3D speckle tracking software (4D LV Analysis, version 3.1.2 and 4D RV Function 2.0; TomTec Imaging Systems, Unterschleissheim, Germany) by an experienced investigator.
For the determination of the LV parameters, apical 4-chamber, 2-chamber, long-axis and short-axis views at end diastole were automatically extracted from the 3D full-volume data sets. Nonforeshortened apical views were identified to select the point of the apex and the center of the mitral annular line connecting both sides of the mitral annulus with the largest LV long-axis dimensions, after which the 3D endocardial surface was automatically reconstructed. Manual adjustments of the endocardial surface were performed when necessary. The same procedure was performed at the end-systolic frame. Subsequently, the software performed 3D speckle tracking analysis throughout the cardiac cycle and generated time domain LV volume curves, from which the 3D LV end-diastolic volume, 3D LV end-systolic volume, and 3D LV ejection fraction (3DLVEF) were determined.
For determination of the RV parameters, nonforeshortened apical 4-and 2-chamber views at end diastole were identified to select the point of the apex and the center of the mitral annular line connecting both sides of the mitral annulus with the largest LV long-axis dimensions. In the apical 3-chamber view, both the anterior and the posterior aortic annuli were identified. In the RV apical 4-chamber and coronal views, the point of the RV apex and the center of the tricuspid annular line were identified. In the short-axis view, both the anterior and the posterior junction between the RV free wall and interventricular septum were identified. In addition, the distance between the interventricular septal and RV free wall was delineated perpendicular to the midpoint of the interventricular septum. The software then automatically reconstructed the RV endocardial surface. Manual editing was performed when required. Subsequently, the software performed speckle tracking analysis throughout the entire cardiac cycle and determined the RV endocardial surface at end systole. When tracking was deemed inadequate, the endocardial surface was manually readjusted as necessary. The software finally provided a time domain RV volume curve, from which the 3D RV end-diastolic volume, 3DRVESV, and 3DRVEF were automatically calculated ( Figure 1 ).
Follow-Up
Follow-up information was obtained regularly in an outpatient clinic. Telephone contacts to patients, physicians, and the next of kin were performed if the patient had been treated in the other hospital. The primary end point was cardiac death. The secondary end point was MACEs, including cardiac death, nonfatal myocardial infarction, ventricular fibrillation, and heart failure exacerbation requiring hospitalization.
Reproducibility
Intraobserver variability was determined by having the observer repeat the measurement of 3DLVEF and 3DRVEF 2 weeks apart in 25 randomly selected patients. Interobserver variability was determined Prognostic Value of 3DRVEF by having a second observer perform these measurements in the same 25 patients. The intra-and interobserver variability values were calculated as the absolute differences between the corresponding 2 measurements in percentages of their mean and intraclass correlation.
Statistical Analysis
Continuous data are expressed as the mean±SD or as the median and interquartile range (25th to 75th percentiles), unless otherwise specified. Normality was evaluated using the Shapiro-Wilk W-test. Categorical data are presented as a number or percentage. The categorical variables were compared using Fisher exact test or χ 2 test as appropriate. A t test or Wilcoxon rank sum test was used to test the differences in the continuous variables between 2 groups according to data distributions. A linear regression analysis was used to study the relationships between 2 parameters. The r value was analyzed as Pearson product-moment correlation coefficient or Spearman rank correlation coefficient. A Bland-Altman analysis was performed to determine bias and the limits of agreement between 2 measurements. We assessed the survival-free status using a Kaplan-Meier analysis, and the prognostic values of the echocardiographic variables were determined using the Cox proportional hazards model. We carefully constructed multivariable models to avoid multicollinearity. Success rate difference and number needed to treat (NNT) were calculated as markers of effect size. 19 The decision-tree models based on echocardiographic parameters for the prediction of subsequent cardiac death and MACE were created using classification and regression-tree (CART) analysis, whereby patients were split into binary groups with the highest contrast for outcome. In CART analysis, the order and hierarchy of variables are selected based on the discriminative power of each variable. In each level of the tree, the variable with the strongest relationship to the end point is selected with the optimal cutoff value. 20 A 2-sided P value <0.05 was considered significant. All statistical analyses were performed using commercial software (JMP, version11; SAS Institute, Inc, Cary, NC and SPSS, version 21; SPSS, Inc, Chicago, IL) and R version 3.1.0. (The R Foundation for Statistical Computing, Vienna, Austria) with the party package.
Results
Protocol 1
The baseline clinical characteristics of the study subjects are depicted in Table I in the Data Supplement. RV volume could be measured in all subjects by both methods. The manual editing of RV endocardial border was required in every case with 3DTTE. Although 3DTTE significantly underestimated the RV volumes compared with CMR (RV end-diastolic volume: 109±42 versus 97±48 mL, P<0.0001; RVESV: 69±39 versus 55±37 mL, P<0.0001), excellent correlations of RV volumes between the 2 methods were noted (r=0.85 and 0.90). The RVEF was significantly larger in 3DTTE (45±10%) than in CMR (39±12%, P<0.0001), with a substantial correlation (r=0.74) ( Figure I in the Data Supplement).
Protocol 2
The baseline clinical and echocardiographic characteristics of the study subjects are demonstrated in Tables 1 and 2 . The median values of 3DLVEF, 3DRVEF, and E/ε′ were 51.3% (interquartile range: 39.7-58.1%), 52.0% (43.2-57.3%), and 13.8% (10.6-20.5%), respectively. There was relatively strong correlation between 3DLVEF and 3DRVEF (r=0.68; P<0.0001). During a median follow-up of 4.1 years (interquartile range: 2.1-5.7 years), 88 patients developed MACE, including 38 cardiac deaths, 5 nonfatal myocardial infarctions, 3 ventricular fibrillation, and 42 heart failures requiring hospitalization. Tables 3 and 4 depict the clinical and echocardiography variables between patients with or without events and their effect sizes expressed as success rate difference and NNT. For cardiac death (Table 3) , 3DRVEF had the smallest NNT (1.36), followed by 3DRVESVI (1.96), 3DLVEF (2.07), ε′ (2.09), and E/ε′ (2.16), suggesting that 3DRVEF had the strongest discrimination. Similarly, 3DRVEF had the smallest NNT (1.60) for MACE, followed by E/ε′ (2.31) and RVESVI (2.48). The NNT of 3DLVEF for MACE was larger than that for cardiac death. Among risk factors, CKD had the smallest NNT of 3.20 for both cardiac death and MACE.
To deal with the different follow-up time, we used Cox proportional hazard model and reported hazard ratio (Tables  II and III in the Data Supplement) . Kaplan-Meyer survival analyses of cardiac death and MACE using median cutoff values of 3DLVEF, 3DRVEF, and E/ε′ showed that they had significant discrimination for future cardiac death and MACE Patients with reduced both EFs were associated with worse outcomes, followed by the group of patients with preserved 3DLVEF but impaired 3DRVEF.
Forward stepwise analyses in the Cox proportional hazard model offering all the variables in the Tables 3 and 4 yielded the following models: 3DRVEF, E/ε′, ε′, and diastolic blood pressure for cardiac death and 3DRVEF, E/ε′, RVESVI, and CKD for MACE. Because 3DRVEF and E/ε′ were chosen for both outcomes and they were the strongest predictors, we drew ROC curves using them (Figure 2) . NNT of 3DRVEF+E/ε′ for cardiac death was 1.31, which was smaller than that of 3DRVEF only (1.36). Similarly, NNT Values are represented as n and mean±SD. LVEDVI indicates left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; NNT, number needed to treat; RVEDVI, right ventricular end-diastolic volume index; RVEF, right ventricular ejection fraction; RVESVI, right ventricular end-systolic volume index; SPAP, systolic pulmonary artery pressure; and SRD, success rate difference. Prognostic Value of 3DRVEF of 3DRVEF+E/e′ for MACE was 1.44, and the value was smaller than that of 3DRVEF only (1.60).
To determine the independent and incremental prognostic value of 3DRVEF, we constructed a nested regression model using above chosen variables in the stepwise analyses. For cardiac death, χ 2 value was significantly increased by adding ε′ and then E/ε′ and further improved by the addition of 3DRVEF, where prognostic significance of E/ε′ disappeared in the final model ( Figure 3A ). For MACE, sequential addition of E/ε′ and RVESVI increased χ 2 value compared with the χ 2 value of the model with CKD. This was further improved by adding 3DRVEF ( Figure 3B) .
Results from the CART decision-tree analyses are summarized in Figure 4 . In this analysis, the variable with the strongest relationship to end point and their optimal cutoff value were determined. For the prediction of cardiac death, the tree allocated 3DRVEF (with cutoff value of 35%) as the first level, followed by E/ε′ (with the cutoff value of 35). The CART tree stratified the patients into 3 risk groups. When the 3DRVEF was ≤35%, cardiac mortality was high (event rate 42%). Patients who had not fulfilled any of these criteria had low event rate (event rate 3%). Similarly, CART chose 3DRVEF as the first, followed by E/ε′ (with cutoff of 35) and normal diastolic function or not for subsequent MACE. The optical cutoff of RVEF for MACE was 41%. This tree stratified the patients into subgroups with incident MACE risk ranging from 1.2% to 63%.
Observer Variability
The intraobserver variability and intraclass correlation for the measurements of 3DLVEF and 3DRVEF were 7.0±4.8% and 7.2±5.1% and 0.96 and 0.97, respectively. The corresponding interobserver variability values were 8.3±5.0% and 7.8±7.4% and 0.83 and 0.86, respectively.
Discussion
To the best of our knowledge, this is the first study to demonstrate the potential prognostic value of 3DRVEF in a large population with diverse cardiac backgrounds. The major findings in this study are summarized as follows: (1) RV volumes and RVEF assessed by 3DTTE correlated well with the corresponding values obtained by CMR; (2) 3DRVEF was significantly associated with both future cardiac death and MACE, similar to E/ε′ and 3DLVEF; (3) 3DRVEF was significantly related to future cardiac events after adjusting for clinical and echocardiographic parameters; and (4) decision-tree analysis (CART) revealed that not 3DLVEF, but 3DRVEF and E/ε′, successfully stratified the patients from low to high risk for subsequent cardiac events.
Previous Studies
The assessment of RV function has become increasingly popular and recognized as important over the past decade. 21 Although 2-dimensional RV free wall strain is a useful predictor of future adverse outcomes in patients with pulmonary hypertension, current RV functional assessment with use of 2-dimensional and Doppler echocardiography parameters has important shortcomings. Because the right ventricle has a complex geometry, 1 or 2-dimensional assessments do not always reflect full aspect of the RV function. 3DTTE-determined RV volumes and RVEF have emerging roles to circumvent this problem. Several previous studies validated the accuracy of RV volume measurements by 3DTTE against CMR reference, although 3DTTE has consistently underestimated RV volumes. [22] [23] [24] [25] With the use of updated RV software, its accuracy and reliability for RV volume measurements has steady improved. 14 Recently updated recommendations for cardiac chamber quantification from the American Society of Echocardiography and the European Association of MACE; B) . Dark blue boxes denote cutoffs and light blue boxes describe the mortality rates. Prognostic Value of 3DRVEF Cardiovascular Imaging described that 3D measurement of RV volumes is recommended when knowledge of RV volumes may be clinically important in laboratories with experiences in 3DTTE. 26 However, there were no studies on the clinical use of 3DTTE-determined RV volumes and RVEF for future prognosis.
Some imaging studies have demonstrated RVEF as a robust predictor of adverse outcomes. The effect of RVEF on adverse outcomes in patients with previous myocardial infarction was investigated using CMR imaging. 3 A RVEF <40% was a significant independent predictor of mortality after adjustments for age, infarct size, and LVEF. Two studies demonstrated the use of RV function assessment by CMR in patients with dilated cardiomyopathy. Gulati et al reported that RVEF<45% was a powerful predictor of adverse cardiac events. 27 Doesch et al 28 described that patients who had preserved LVEF and reduced RVEF had a significantly worse prognosis than patients with reduced LVEF and preserved RVEF. Another nuclear cardiology study was conducted to evaluate the effects of RVEF on outcomes in 733 patients with chronic heart failure and depressed LVEF (≤35%). 29 A RVEF <20% was associated with a significant risk of future cardiovascular events. Although all of these studies clearly demonstrated the potential clinical value of RVEF for the prediction of future cardiac events, CMR and nuclear studies could not be performed in every patient because of cost, availability, and several specific shortcomings.
Current Study
First, we validated the accuracy of RV volumes and RVEF measurements by 3DTTE against CMR in this study. With the use of new RV analytic software, RV volumes measured by 3DTTE correlated well with the corresponding values obtained by CMR with some underestimation. 25 However, the manual editing of RV endocardial surface was required in every patient, and the findings were consistent with the recent publication.
14 Second, we determined the prognostic value of 3DRVEF in a large number of patients with wide range of cardiac function. We demonstrated that 3DRVEF is significantly associated with future cardiovascular events. Using sequential and nested regression models including the variables selected by a stepwise forward procedure in Cox proportional hazard analysis, we established an incremental value of 3DRVEF over the other echocardiography parameters for predicting adverse outcomes. Our results clearly showed that 3DRVEF is an independent predictor of cardiac death and MACE.
LVEF has been widely established as one of the most important parameters for the assessment of cardiac function and for predicting future adverse events. Interestingly, 3DLVEF was not chosen in both a stepwise Cox proportional hazard analysis and a decision-tree analysis for outcomes in our study. 3DRVEF and diastolic function parameters were selected as the highest ranked predictors of subsequent cardiovascular events. Even more intriguingly, the CART allocated 3DRVEF before any of diastolic functional parameters. Although the importance and superiority of diastolic function over systolic counterpart have been reported in the literature, 30 this is the first time to verify the superiority of RVEF over E/ε′. The main reason why the cutoff value of E/ε′ from the CART analysis was so high (E/ε′=35) compared with generally accepted value was that in the decision-tree model, many patients with diastolic dysfunction had been already classified into the group with impaired 3DRVEF at the first node of the decision tree. Thus, the patients who were classified into the better RV function group but developed future events had extremely impaired diastolic function, resulting in the higher cutoff value more than expected. The cutoff values for 3DRVEF were ≈35% to 40%, which corroborates with the previous results. 3, 27, 29 The proposed reason for superiority of RV function over LV function may be related to the fact that RV function is comparable or more powerful parameters for exercise tolerance and prognoses compared with LV function 3, [27] [28] [29] [31] [32] [33] and that RVEF makes the prognostic power of LVEF attenuated in multivariable models. 3, 28 We think that 3DRVEF provides significant prognostic value for future outcome.
Clinical Implications
This study offers the first evidence that 3DRVEF has a powerful prognostic value in clinical practice. Assessment of 3DRVEF is theoretically superior to traditional 2-dimensional echocardiography estimates of RV function and is more widely adopted compared with CMR measurements of RVEF. Our results stress the routine use of 3DTTE for the measurements of RV volumes and RVEF to predict future prognoses. The incorporation of RV functional parameters with LV systolic and diastolic function parameters may provide more accurate information on ventricular function and future prognoses.
Study Limitations
Several limitations in the current study merit discussion. First, the prognostic assessments in this study were retrospective. There was a risk of selection bias because 3DTTE acquisition was performed in patients with relatively good image quality. Therefore, the results may not apply to the general population. Second, manual RV border editing was performed in every case with use of the current RV software because of the complex shape of the RV cavity. Further refinement of the software could overcome this problem. Third, we did not incorporate 3DTTE global strain variables because the current RV software does not provide 3DTTE RV strain values. Future studies should be performed to determine the prognostic superiority of 3D global strain in both ventricles over biventricular ejection fraction assessed by 3DTTE. Last, the decision trees from CART analyses optimized to our population, which warrants future external validation.
Conclusions
3DRVEF is a significant predictor of cardiac death and major cardiac events in patients with diverse cardiac pathologies. 3DRVEF also offered the incremental value over LV systolic and diastolic parameters for predicting future adverse outcomes.
